Vaccines in Pregnancy: Progress and Research- Focus on Group B Streptococcus
* You will be redirected to the BCM DCPD credit management site when claiming credit and may be asked to register or log in.
In this presentation, Dr. Flor Munoz-Rivas describes group B streptococcus (GBS) and the role of maternal immunization in neonatal and maternal protection against this infection. Dr. Munoz-Rivas also highlights the GBS vaccines currently in development.
This Obstetrics and Gynecology Grand Rounds session took place on December 18, 2024 at 8:00 a.m.
Activity Information
How to Claim Credit
You may claim credit after watching this activity.
You will be redirected to the BCM DCPD credit management site when claiming credit and may be asked to register or log in.
Needs Statement
Physicians, fellows, residents, medical students, and other healthcare professionals need to receive regular updates on practice guidelines, the latest scientific advances, and translational efforts in the field of Obstetrics and Gynecology. The series aims to increase the knowledge and skills of the learners in select topic areas to improve the diagnosis, treatment, and management of obstetric and gynecologic disorders. The series will also address unique ethical challenges in the field.
Educational Objectives
At the conclusion of the session, the participants should be able to:
- Review burden of group B streptococcus (GBS) on maternal and infant health.
- Explain the role of maternal immunization in maternal and neonatal protection against GBS.
- Discuss GBS vaccines in development.
Target Audience
Professional Categories
- Physicians
- Medical Students
- Fellows
- Residents
Specialties
- Infectious Disease
- Obstetrics and Gynecology
Interest Groups
- Hospital Medicine
- Primary Care
Activity Evaluation
Evaluation by questionnaire will address program content, presentation, and possible bias.
Educational Methods
- Lectures
- Case Presentations
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Activity Director
Term of Approval
December 1, 2024 through December 31, 2026. Original release date: December 1, 2024.
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
Levels and trends in child mortality: Report 2021. World Health Organization. December 12, 2021. Accessed February 21, 2025. https://www.who.int/publications/m/item/levels-and-trends-in-child-mortality-report-2021.
Mohsin N, Keenan L, Guo J. Latest child mortality estimates reveal world remains off track to Meeting Sustainable Development Goals. World Health Organization. December 20, 2021. Accessed February 21, 2025. https://www.who.int/news/item/20-12-2021-latest-child-mortality-estimates-reveal-world-remains-off-track-to-meeting-sustainable-development-goals.
Perin J, Mulick A, Yeung D, et al. Global, regional, and national causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the Sustainable Development Goals [published correction appears in Lancet Child Adolesc Health. 2022 Jan;6(1):e4. doi: 10.1016/S2352-4642(21)00382-5.]. Lancet Child Adolesc Health. 2022;6(2):106-115. doi:10.1016/S2352-4642(21)00311-4.
Doran KS, Nizet V. Molecular pathogenesis of neonatal group B streptococcal infection: no longer in its infancy. Mol Microbiol. 2004;54(1):23-31. doi:10.1111/j.1365-2958.2004.04266.x.
Active bacterial core surveillance. Centers for Disease Control and Prevention. May 15, 2024. Accessed February 21, 2025. https://www.cdc.gov/abcs/about/index.html.
Gonçalves BP, Procter SR, Paul P, et al. Group B streptococcus infection during pregnancy and infancy: estimates of regional and global burden [published correction appears in Lancet Glob Health. 2022 Jul;10(7):e960. doi: 10.1016/S2214-109X(22)00235-2.]. Lancet Glob Health. 2022;10(6):e807-e819. doi:10.1016/S2214-109X(22)00093-6.
Ohuma EO, Moller AB, Bradley E, et al. National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis [published correction appears in Lancet. 2024 Feb 17;403(10427):618. doi: 10.1016/S0140-6736(24)00267-8.]. Lancet. 2023;402(10409):1261-1271. doi:10.1016/S0140-6736(23)00878-4.
Mahtab S, Madewell ZJ, Madhi SA, et al. Stillbirths and Neonatal Deaths Caused by Group B Streptococcus in Africa and South Asia Identified Through Child Health and Mortality Prevention Surveillance (CHAMPS). Open Forum Infect Dis. 2023;10(9):ofad356. Published 2023 Jul 11. doi:10.1093/ofid/ofad356.
Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646. doi:10.1155/2012/985646.
Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715-725. doi:10.1038/nri2155.
BAKER CJ, EDWARDS MS. Group B streptococcal infections. Annals of the New York Academy of Sciences. 1988;549(1):193-202. doi:10.1111/j.1749-6632.1988.tb23972.x.
Guidelines for vaccinating pregnant women. Centers for Disease Control and Prevention. July 12, 2024. Accessed February 21, 2025. https://www.cdc.gov/vaccines-pregnancy/hcp/vaccination-guidelines.
Le Doare K, Kampmann B, Vekemans J, et al. Serocorrelates of protection against infant group B streptococcus disease. Lancet Infect Dis. 2019;19(5):e162-e171. doi:10.1016/S1473-3099(18)30659-5.
Vekemans J, Crofts J, Baker CJ, et al. The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations. Vaccine. 2019;37(24):3190-3198. doi:10.1016/j.vaccine.2019.04.039.
Heyderman RS, Madhi SA, French N, et al. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial. Lancet Infect Dis. 2016;16(5):546-555. doi:10.1016/S1473-3099(15)00484-3.
Buurman ET, Timofeyeva Y, Gu J, et al. A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization. J Infect Dis. 2019;220(1):105-115. doi:10.1093/infdis/jiz062.
Seale AC, Baker CJ, Berkley JA, et al. Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions. Vaccine. 2019;37(35):4877-4885. doi:10.1016/j.vaccine.2019.07.012.
Madhi SA, Anderson AS, Absalon J, et al. Potential for maternally administered vaccine for Infant Group B streptococcus. New England Journal of Medicine. 2023;389(3):215-227. doi:10.1056/nejmoa2116045.
Pena JM, Lannes-Costa PS, Nagao PE. Vaccines for streptococcus agalactiae: Current status and future perspectives. Frontiers in Immunology. 2024;15. doi:10.3389/fimmu.2024.1430901.
Buurman ET, Timofeyeva Y, Gu J, et al. A novel hexavalent capsular polysaccharide conjugate vaccine (GBS6) for the prevention of neonatal group B streptococcal infections by maternal immunization. The Journal of Infectious Diseases. 2019;220(1):105-115. doi:10.1093/infdis/jiz062.
Absalon J, Segall N, Block SL, et al. Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial. Lancet Infect Dis. 2021;21(2):263-274. doi:10.1016/S1473-3099(20)30478-3.
Our pipeline. MinervaX. June 7, 2024. Accessed February 21, 2025. https://minervax.com/innovation/our-pipeline/.
Dangor Z, Kwatra G, Pawlowski A, et al. Association of infant Rib and Alp1 surface protein N-terminal domain immunoglobulin G and invasive Group B Streptococcal disease in young infants. Vaccine. 2023;41(10):1679-1683. doi:10.1016/j.vaccine.2023.01.071.
Immunogenicity and Safety of GBS-NN/ NN2 in Pregnant Women. Clinicaltrials.gov. January 13, 2025. Accessed February 21, 2025. https://clinicaltrials.gov/study/NCT05154578.
Clinicaltrials.gov. August 8, 2023. Accessed February 21, 2025. https://clinicaltrials.gov/study/NCT04596878.
Absalon J, Simon R, Radley D, et al. Advances towards licensure of a maternal vaccine for the Prevention of Invasive Group B streptococcus disease in infants: A discussion of different approaches. Human Vaccines & Immunotherapeutics. 2022;18(1). doi:10.1080/21645515.2022.2037350.
Madhi SA, Koen A, Cutland CL, et al. Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy. Clin Infect Dis. 2017;65(11):1897-1904. doi:10.1093/cid/cix666.
Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307-1326. doi:10.1084/jem.129.6.1307.
Eskola J, Käyhty H, Takala AK, et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasivehaemophilus influenzaetype B disease. New England Journal of Medicine. 1990;323(20):1381-1387. doi:10.1056/nejm199011153232004.
Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007;25(19):3816-3826. doi:10.1016/j.vaccine.2007.01.119.
Parikh SR, Andrews NJ, Beebeejaun K, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775-2782. doi:10.1016/S0140-6736(16)31921-3.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenter
-
Flor Munoz-Rivas, M.D.
Associate Professor of Pediatrics and Infectious Diseases
Baylor College of Medicine
Disclosure:
- Research Support: Pfizer
- Advisory Committee Membership: Pfizer
Activity Director
-
Tara J Harris, M.D., FACOG
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Planning Committee Members
-
Jennifer Michele Magdalen Bump, M.D., M.B.A.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Simon Dadoun, M.D.
Obstetrics and Gynecology Resident
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Roopali Donepudi, M.D.
Assistant Professor
https://www.bcm.edu/people-search/roopali-donepudi-20713
Disclosure:
Nothing to disclose.
-
Tiara Gatewood, M.A., M.B.A.
Academic Coordinator
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Tara J Harris, M.D., FACOG
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Health Topics
Presenter: